Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei
Sharon J. Peacock*

, Herbert P. Schweizer†, David A.B. Dance‡, Theresa L. Smith§, Jay E. Gee§, Vanaporn Wuthiekanun*, David DeShazer¶, Ivo Steinmetz#, Patrick Tan, and Bart J. Currie††
Author affiliations: *Mahidol University, Bangkok, Thailand; †Colorado State University, Fort Collins, Colorado, USA; ‡Health Protection Agency (South West), Plymouth, UK; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ¶US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; #Universität Greifswald, Greifswald, Germany; **Genome Institute of Singapore, Singapore; ††Menzies School of Health Research and Royal Darwin Hospital, Darwin, Northern Territory, Australia;
Main Article
Table 3
Treatment of melioidosis
Initial parenteral therapy |
Ceftazidime 50 mg/kg/dose (up to 2 g) every 6–8 h,* or meropenem 25 mg/kg/dose (up to 1 g) every 8 h* |
Duration of therapy a minimum of 10–14 d, and longer (4–8 wk) for deep-seated infection
|
Oral eradication therapy |
Trimethoprim-sulfamethoxazole orally every 12 h
2 × 160–800 mg (960 mg) tablets if >60 kg, 3 × 80–400 (480 mg) tablets if 40–60 kg, and 1 × 160–800 mg (960 mg) or 2 × 80–400 (480 mg) tablets if adult <40 kg; ± doxycycline 2.5 mg/kg/dose up to 100 mg orally every 12 h plus folate 5 mg/d
Duration at least 3–6 mo |
Main Article
Page created: July 12, 2010
Page updated: July 12, 2010
Page reviewed: July 12, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.